GL1X · GenesisL1 explorer

MolNFT v1 · #183465 · protein

Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2

7NQW: “Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of…”. X-ray diffraction, 2 ligands (UNW, SO4). MolNFT v1 #183465 on GenesisL1: 3D structure, binding sites and pockets in GL1X.

PDB
7NQW
Type
protein
Length
346 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
UniProt
P28482
Ligands
UNW, SO4

Structure

x-ray diffraction · 1 distinct chain.

ChainMoleculeTypeResiduesSecondary structureUniProt
A—protein346—P28482

Ligands and binding sites

  • UNW · 6-[5-chloranyl-2-(oxan-4-ylamino)pyrimidin-4-yl]-2-[2-oxidanylidene-2-(1,3,4,5-tetrahydro-2-benzazepin-2-yl)ethyl]-3~{H}-isoindol-1-one · ligand · chains A
  • SO4 · Sulfate ion · ion · 2 copies · chains A
  • DMS · Dimethyl sulfoxide · additive · 2 copies · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Compared structures

  • 7NQW · Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.